A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
Status:
Active, not recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This prospective study is designed to evaluate the efficacy, safety, and tolerability of
ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and
pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a
background of stable heart failure therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Alexion Pharmaceuticals
Collaborators:
Eidos Therapeutics Eidos Therapeutics, a BridgeBio company